Product correctly added to cart.

discount label
PAT-048
View 3D

Biosynth logo

PAT-048

CAS: 1359983-15-5

Ref. 3D-JEC98315

1mgTo inquire
5mgTo inquire
10mgTo inquire
25mgTo inquire
Estimated delivery in United States, on Thursday 27 Jun 2024

Product Information

Name:
PAT-048
Description:

PAT-048 is a molecule that has been shown to be effective in vitro for the treatment of scleroderma by inducing cell growth and collagen production. It activates signal transducer and activator of transcription (STAT) proteins, which activate gene expression and regulate cellular proliferation. In vitro studies have also shown that PAT-048 can induce the activation of STATs in red blood cells and in red blood cells treated with bleomycin. This drug is currently undergoing preclinical development, but it may be capable of treating other diseases such as arthritis or chronic obstructive pulmonary disease.

6-Fluoro-3-indoxyl-beta-D-galactopyranoside is an antituberculosis drug that belongs to the class of rifamycins. It is the most active of the rifamycins for the treatment of tuberculosis. Rifapentine inhibits bacterial growth by binding to DNA-dependent RNA polymerase, thereby preventing transcription and replication.

Brand:
Biosynth
Long term storage:
Notes:

Chemical properties

Molecular weight:
461.9 g/mol
Formula:
C22H18ClF2N3O2S
Purity:
Min. 95%
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: 3D-JEC98315 PAT-048

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".